| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | Entrez:930 MIM:107265 HGNC:HGNC:1633 Ensembl:ENSG00000177455 AllianceGenome:HGNC:1633 | |
| Description | CD19 molecule | |||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding | |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | Entrez:931 MIM:112210 HGNC:HGNC:7315 Ensembl:ENSG00000156738 AllianceGenome:HGNC:7315 | |
| Description | membrane spanning 4-domains A1 | |||||
| GTO ID | GTC1938 |
| Trial ID | NCT03605238 |
| Disease | Neuromyelitis Optica |
| Altered gene | CD19|CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD20 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Withdrawn |
| Title | Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20 |
| Year | 2018 |
| Country | China |
| Company sponsor | Chinese PLA General Hospital |
| Other ID(s) | CHN-PLAGH-NO-S2018-002-02 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||
|
|||||||||||